NCT04338503 is a clinical trial of Partial IVC occlusion in Heart Failure, sponsored by Cardioflow Technologies, LLC.

Who is sponsoring NCT04338503?

NCT04338503 is sponsored by Cardioflow Technologies, LLC.

What drugs are being tested in NCT04338503?

Interventions in NCT04338503: Partial IVC occlusion.

What condition does NCT04338503 study?

NCT04338503 studies Heart Failure.

Is NCT04338503 still recruiting?

NCT04338503 is currently status unknown. Last updated 30 March 2023.

Last reviewed 2023-03-30 · How we verify

NCT04338503

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mechanically Optimizing Cardiac Preload in Heart Failure Patients

Status unknown Last updated 30 March 2023

What this trial tests

trial testing Partial IVC occlusion in Heart Failure in 10 participants. Status unknown.

Timeline

1 September 2021

Primary endpoint
30 June 2024

30 June 2024

Quick facts

Lead sponsor	Cardioflow Technologies, LLC
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	10
Start date	1 September 2021
Primary completion	30 June 2024
Estimated completion	30 June 2024
Sites	1 location across United States

Drugs / interventions tested

Partial IVC occlusion

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Cardioflow Technologies, LLC

Who can join

Adults 18 to 80, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the current study is to determine if partial balloon occlusion of the inferior vena cava can optimize cardiac pre-load and subsequently pulmonary pressures and cardiac output as a novel method to unload pulmonary edema and other symptoms of decompensated congestive heart failure. All products in this study are FDA approved and adhere to the specifications of the intended use.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04338503 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cardioflow Technologies, LLC
Last refreshed: 30 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04338503.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing